Department of Medicinal Chemistry, Faculty of Pharmacy, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland.
Department of Pathophysiology, Faculty of Medicine, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland.
Molecules. 2021 Sep 16;26(18):5632. doi: 10.3390/molecules26185632.
During forced degradation, the intrinsic stability of active pharmaceutical ingredients (APIs) could be determined and possible impurities that would occur during the shelf life of the drug substance or the drug product could be estimated. Vildagliptin belongs to relatively new oral antidiabetic drugs named gliptins, inhibiting dipeptidyl peptidase 4 (DPP-4) and prolonging the activities of the endogenous incretin hormones. At the same time, some gliptins were shown as prone to degradation under specific pH and temperature conditions, as well as in the presence of some reactive excipients. Thus, forced degradation of vildagliptin was performed at high temperature in extreme pH and oxidative conditions. Then, selective LC-UV was used for quantitative determination of non-degraded vildagliptin in the presence of its degradation products and for degradation kinetics. Finally, identification of degradation products of vildagliptin was performed using an UHPLC-DAD-MS with positive ESI. Stability of vildagliptin was also examined in the presence of pharmaceutical excipients, using mid-IR and NIR with principal component analysis (PCA). At 70 °C almost complete disintegration of vildagliptin occurred in acidic, basic, and oxidative media. What is more, high degradation of vildagliptin following the pseudo first-order kinetics was observed at room temperature with calculated k values 4.76 × 10 s, 3.11 × 10 s, and 1.73 × 10 s for oxidative, basic and acidic conditions, respectively. Next, new degradation products of vildagliptin were detected using UHPLC-DAD-MS and their molecular structures were proposed. Three degradants were formed under basic and acidic conditions, and were identified as [(3-hydroxytricyclo- [3.3.1.13,7]decan-1-yl)amino]acetic acid, 1-{[(3-hydroxytricyclo[3.3.1.13,7]decan-1-yl)amino]acetyl}-pyrrolidine-2-carboxylic acid and its -methyl ester. The fourth degradant was formed in basic, acidic, and oxidative conditions, and was identified as 1-{[(3-hydroxytricyclo[3.3.1.13,7]-decan-1-yl)amino]acetyl}pyrrolidine-2-carboxamide. When stability of vildagliptin was examined in the presence of four excipients under high temperature and humidity, a visible impact of lactose, mannitol, magnesium stearate, and polyvinylpirrolidone was observed, affecting-NH- and CO groups of the drug. The obtained results (kinetic parameters, interactions with excipients) may serve pharmaceutical industry to prevent chemical changes in final pharmaceutical products containing vildagliptin. Other results (e.g., identification of new degradation products) may serve as a starting point for qualifying new degradants of vildagliptin as it is related to substances in pharmacopoeias.
在强制降解过程中,可以确定活性药物成分(APIs)的固有稳定性,并可以估计药物物质或药物产品在货架期内可能出现的潜在杂质。维格列汀属于相对较新的口服抗糖尿病药物,称为gliptins,抑制二肽基肽酶 4(DPP-4)并延长内源性肠降血糖素的活性。同时,一些gliptins在特定的 pH 和温度条件下以及某些反应性赋形剂存在下显示出易于降解的特性。因此,在高温、极端 pH 和氧化条件下对维格列汀进行强制降解。然后,采用选择性 LC-UV 法在其降解产物存在下定量测定未降解的维格列汀,并进行降解动力学研究。最后,采用带有正电喷雾的 UHPLC-DAD-MS 对维格列汀的降解产物进行鉴定。还使用中红外和近红外与主成分分析(PCA)法,在存在药物赋形剂的情况下检查维格列汀的稳定性。在酸性、碱性和氧化介质中,70°C 时维格列汀几乎完全崩解。更重要的是,在室温下观察到维格列汀的高降解遵循伪一级动力学,计算得到的 k 值分别为 4.76×10-1 s-1、3.11×10-1 s-1 和 1.73×10-1 s-1,分别用于氧化、碱性和酸性条件。接下来,使用 UHPLC-DAD-MS 检测到维格列汀的新降解产物,并提出了它们的分子结构。在碱性和酸性条件下形成了三种降解产物,鉴定为[(3-羟基三环[3.3.1.13,7]癸烷-1-基)氨基]乙酸、1-[(3-羟基三环[3.3.1.13,7]癸烷-1-基)氨基乙酰]-吡咯烷-2-羧酸及其甲酯。第四种降解产物在碱性、酸性和氧化条件下形成,鉴定为 1-[(3-羟基三环[3.3.1.13,7]-癸烷-1-基)氨基乙酰]吡咯烷-2-甲酰胺。当在高温高湿条件下检查维格列汀与四种赋形剂共存时的稳定性时,观察到乳糖、甘露醇、硬脂酸镁和聚乙烯吡咯烷酮的可见影响,影响药物的-NH-和 CO 基团。所得结果(动力学参数、与赋形剂的相互作用)可用于制药行业,以防止含有维格列汀的最终药物产品发生化学变化。其他结果(例如,鉴定新的降解产物)可作为鉴定维格列汀新降解产物的起点,因为它与药典中的物质有关。